Research programme: apolipoprotein A-I stimulants - VIRxSYSAlternative Names: Lipid disorders gene therapy - VIRxSYS; Research programme - dyslipidemia gene therapy - VIRxSYS; SMaRT ApoA1; VRX1243
Latest Information Update: 17 Feb 2011
At a glance
- Originator Intronn
- Developer VIRxSYS Corporation
- Class Gene therapies
- Mechanism of Action Apolipoprotein A I stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Dyslipidaemias